Results 1 to 10 of about 38,154 (222)

Discovery and development of Factor Xa inhibitors (2015-2022). [PDF]

Front Pharmacol, 2023
As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT).
Zheng W, Dai X, Xu B, Tian W, Shi J.
europepmc   +2 more sources

Expedited surgery does not increase transfusion rates for patients with geriatric hip fracture taking factor Xa inhibitors. [PDF]

OTA Int, 2023
. Objectives:. Geriatric patients who sustain hip fractures and are taking factor Xa inhibitors (Xa-I) experience surgical delay. Our institution developed a pharmacokinetic protocol to formally guide and expedite surgical timing for these patients.
Wang J, Nilssen P, Stone J, Breda K, Little M, Moon C, Lin C.   +6 more
europepmc   +2 more sources

Predictors of hematoma expansion in intracerebral hemorrhage associated with factor Xa inhibitors. [PDF]

Front Neurol
BackgroundImproving the outcomes of patients with intracerebral hemorrhage (ICH) associated with factor Xa inhibitors remains a clinical challenge. Andexanet alfa, a specific reversal agent for factor Xa inhibitors, has the potential to mitigate hematoma
Komatsu Y, Koiso T, Sekine T, Akutagawa K, Karita H, Kikuchi N, Yamazaki T.   +6 more
europepmc   +2 more sources

Factor Xa inhibitors in hemodialysis: OK-for now! [PDF]

Proc (Bayl Univ Med Cent), 2023
Banchs JE.
europepmc   +1 more source

Urine-based point-of-care testing for factor-Xa-inhibitors in acute ischemic stroke patients: a feasibility study. [PDF]

Front Neurol, 2023
Doeppner TR, Olbricht L, Maxhuni T, Alhaj Omar O, Sachs UJ, Juenemann MB, Huttner HB, Gerner ST.   +7 more
europepmc   +1 more source

The 5 most frequently asked questions about factor Xa inhibitors. [PDF]

Hematology Am Soc Hematol Educ Program, 2022
Wang TF, Carrier M.
europepmc   +1 more source

Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. [PDF]

Cochrane Database Syst Rev, 2023
Li M, Li J, Wang X, Hui X, Wang Q, Xie S, Yan P, Tian J, Li J, Xie P, Yang K, Yao L.   +11 more
europepmc   +1 more source

The impact of body composition variability on coagulation monitoring in patients on direct oral factor Xa inhibitors for treatment of venous thromboembolism. [PDF]

Front Cardiovasc Med
Kurzmann-Guetl K, Leitner DR, Gary T, Avian A, Beck A, Rabensteiner J, Prueller F, Raggam RB, Brodmann M, Toplak H.   +9 more
europepmc   +1 more source

Incomplete harms reporting in systematic reviews of direct oral factor Xa inhibitors. [PDF]

Blood Adv
Rea J, Lee C, Kee M, Rucker B, Flores H, Walters C, Haney T, Tomlin A, Khan A, Vassar M.   +9 more
europepmc   +1 more source

Position statement of the Polish Society of Gastroenterology on the use of andexanet alfa in patients with gastrointestinal bleeding taking factor Xa inhibitors. [PDF]

Prz Gastroenterol
Adrych K, Daniluk J, Nowakowska-Duława E, Białek A, Rydzewska GM.   +4 more
europepmc   +1 more source